Rhinomed Limited
RHNMF · OTC
6/30/2023 | 6/30/2022 | 6/30/2021 | 6/30/2020 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -17.9% | 133.8% | 9.2% | – |
| Gross Profit | -$0 | $0 | $0 | $0 |
| % Margin | -2.5% | 68.2% | 70.7% | 59.3% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -121.7% | -49.8% | -205.5% | -187.3% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -146% | -58% | -221.8% | -203.8% |
| EPS Diluted | -0.038 | -0.02 | -0.034 | -0.044 |
| % Growth | -89.1% | 40.2% | 23.2% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |